ArticleBone marrow research2012
Role of HLA in Hematopoietic Stem Cell Transplantation.
Article in Bone marrow research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02307435 (Potency of Allogenic Bone Marrow, Umbilical Cord, Adipose Mesenchymal Stem Cell for Non Union Fracture and Long Bone Defect, Directly and Cryopreserved), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Potency of Allogenic Bone Marrow, Umbilical Cord, Adipose Mesenchymal Stem Cell for Non Union Fracture and Long Bone Defect, Directly and Cryopreserved
Who cites it
14 citing papers in PubMed.
- Factors Affecting Immune Reconstitution Post-Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination.European journal of haematology · 2026Review
- Review
- A donor PD-1Signal transduction and targeted therapy · 2025Article
- Advancements in HLA Typing Techniques and Their Impact on Transplantation Medicine.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024Review
- Review
- HLA-based banking of induced pluripotent stem cells in Saudi Arabia.Stem cell research & therapy · 2023Article
- Article
- Urine-derived stem cells in neurological diseases: current state-of-the-art and future directions.Frontiers in molecular neuroscience · 2023Review
- Mesenchymal Stem Cell Transplantation for Ischemic Diseases: Mechanisms and Challenges.Tissue engineering and regenerative medicine · 2021Review
- A concise review on factors influencing the hematopoietic stem cell transplantation main outcomes.Health science reports · 2021Review
- The distribution of HLA haplotypes in the ethnic groups that make up the Brazilian Bone Marrow Volunteer Donor Registry (REDOME).Immunogenetics · 2018Article
- Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor.The Journal of clinical investigation · 2016Article
- Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT.Bone marrow transplantation · 2014Article
- Inference of high resolution HLA types using genome-wide RNA or DNA sequencing reads.BMC genomics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The selection of hematopoietic stem cell transplantation (HSCT) donors includes a rigorous assessment of the availability and human leukocyte antigen (HLA) match status of donors. HLA plays a critical role in HSCT, but its involvement in HSCT is constantly in flux because of changing technologies and variations in clinical transplantation results. The increased availability of HSCT through the use of HLA-mismatched related and unrelated donors is feasible with a more complete understanding of permissible HLA mismatches and the role of killer-cell immunoglobulin-like receptor (KIR) genes in HSCT. The influence of nongenetic factors on the tolerability of HLA mismatching has recently become evident, demonstrating a need for the integration of both genetic and nongenetic variables in donor selection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.